A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
| dc.contributor.author | Hickish, T | |
| dc.contributor.author | Cassidy, J | |
| dc.contributor.author | Propper, D | |
| dc.contributor.author | Chau, I | |
| dc.contributor.author | Falk, S | |
| dc.contributor.author | Ford, H | |
| dc.contributor.author | Iveson, T | |
| dc.contributor.author | Braun, Michael S | |
| dc.contributor.author | Potter, V | |
| dc.contributor.author | Macpherson, I | |
| dc.contributor.author | Finnigan, H | |
| dc.contributor.author | Lee, C | |
| dc.contributor.author | Jones, H | |
| dc.contributor.author | Harrison, M | |
| dc.date.accessioned | 2015-01-22T15:29:47Z | |
| dc.date.available | 2015-01-22T15:29:47Z | |
| dc.date.issued | 2014-12 | |
| dc.identifier.citation | A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. 2014, 50 (18):3136-44 Eur J Cancer | en |
| dc.identifier.issn | 1879-0852 | |
| dc.identifier.pmid | 25441408 | |
| dc.identifier.doi | 10.1016/j.ejca.2014.08.008 | |
| dc.identifier.uri | http://hdl.handle.net/10541/338695 | |
| dc.description.abstract | This randomised phase II trial aimed to compare efficacy of the irreversible ErbB family blocker, afatinib, with cetuximab in patients with KRAS wild-type metastatic colorectal adenocarcinoma (mCRC) with progression following oxaliplatin- and irinotecan-based regimens. Efficacy in patients with KRAS mutations was also evaluated. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to European journal of cancer (Oxford, England : 1990) | en |
| dc.title | A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. | en |
| dc.type | Article | en |
| dc.contributor.department | Poole Hospital and Bournemouth University, Longfleet Road, Poole, Dorset BH15 2JB, UK. | en |
| dc.identifier.journal | European Journal of Cancer | en |
| html.description.abstract | This randomised phase II trial aimed to compare efficacy of the irreversible ErbB family blocker, afatinib, with cetuximab in patients with KRAS wild-type metastatic colorectal adenocarcinoma (mCRC) with progression following oxaliplatin- and irinotecan-based regimens. Efficacy in patients with KRAS mutations was also evaluated. |